Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, ...

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

Harrington Prize for Innovation in Medicine has been awarded to Owen N. Witte, MD, Distinguished University Professor and President's Chair in Developmental Immunology, David Geffen School of Medicine ...

First-in-class Bruton’s tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs SAN FRANCISCO, March 17, 2025 (GLOBE ...

The Harrington Discovery Institute at University Hospitals and the American Society for Clinical Investigation have awarded Dr. Owen Witte(Link is external) (Link opens in new window) with the twelfth ...

National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...